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Background:  In  Guinea-Bissau  we  conducted  three  trials  of  neonatal  vitamin  A supplementation  (NVAS)
from 2002  to  2008.  None  of the  trials  found  a  beneﬁcial  effect  on  mortality.  From  2003  to  2007,  an  early
measles  vaccine  (MV)  trial was  ongoing,  randomizing  children  1:2 to  early  MV at 4.5 months  or  no  early
MV,  in  addition  to the  usual  MV  at 9 months.  We  have  previously  found  interactions  between  vitamin  A
and  vaccines.
Objective:  We  investigated  whether  there  were  interactions  between  NVAS  and  early  MV.
Design:  We  compared  the  mortality  of NVAS  and  placebo  recipients:  ﬁrst,  from  4.5 to 8 months  for  children
randomized  to early  MV  or  no early  MV;  and  second,  from  9 to 17  months  in  children  who  had  received
two  MV  or  one  MV.  Mortality  rates  (MR)  were  compared  in  Cox  models  producing  mortality  rate  ratios
(MRR).
Results: A  total  of 5141  children  were  randomized  to NVAS  (N = 3015)  or placebo  (N  = 2126)  and  were
later  randomized  to  early  MV (N =  1700)  or no  early  MV  (N = 3441).  Between  4.5 and 8 months,  NVAS
compared  with  placebo  was  associated  with  higher  mortality  in  early  MV  recipients  (MR  = 30  versus
MR  =  0,  p =  0.01),  but  not  in  children  who  did  not  receive  early  MV (p for  interaction  between  NVAS  and
early  MV  = 0.03).  From  9 to 17  months  NVAS  was  not  associated  with  mortality.  Overall,  from  4.5 to 17
months  NVAS  was  associated  with  increased  mortality  in early  MV  recipients  (Mortality  rate  ratio  = 5.39
(95% conﬁdence  interval:  1.62,  17.99)).
Conclusions:  These  observations  indicate  that  NVAS  may  interact  with  vaccines  given several  months
later.  This  may  have  implications  for the  planning  of  future  child  intervention  programs.
©  2014  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Neonatal vitamin A supplementation (NVAS) is currently under
nvestigation as a public health intervention to combat vitamin
 deﬁciency and mortality in areas afﬂicted by vitamin A deﬁ-
iency. We have studied the effect of NVAS on infant mortality
 Clinical trial registration: The trials were registered at clinicaltrials.gov (VITA I:
CT00168597; VITA II and III: NCT00168610; Early MV trial: NCT00168558).
∗ Corresponding author at: Research Center for Vitamins and Vaccines (CVIVA),
andim Health Project, Statens Serum Institut, 5 Artillerivej, DK-2300 Copenhagen,
enmark. Tel.: +45 3268 8354; fax: +45 3268 3868.
E-mail address: cb@ssi.dk (C.S. Benn).
ttp://dx.doi.org/10.1016/j.vaccine.2014.07.090
264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unlicense  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
in three randomized trials in Guinea-Bissau. One trial randomized
normal birth weight neonates (≥2500 g) 1:1 to 50,000 IU vitamin
A or placebo (VITA I, 2002–2004) [1]. A second trial randomized
low birth weight neonates (<2500 g) 1:1 to 25,000 IU vitamin A
or placebo (VITA II, 2005–2008) [2]. A third trial randomized nor-
mal  birth weight neonates 1:1:1 to 50,000 IU vitamin A, 25,000 IU
vitamin A or placebo (VITA III, 2004–2007) [3].
We observed that NVAS interacted with subsequent routine
vaccinations in a sex-differential manner; the effect of NVAS
tended to be negative in females once they started receiving the
diphtheria–tetanus–pertussis vaccine (DTP) recommended at 6
weeks of age [2,4].
From 2003 to 2007 a trial randomizing children to early measles
vaccine (MV) at 4.5 months of age or no early MV in addition to
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Table  1
The three neonatal vitamin A trials in Guinea-Bissau.
VITA I VITA II VITA III
Enrollment period 11/2002–11/2004 05/2005–01/2008 11/2004–05/2007
Recruitment area BHP study area BHP study area and Bissau City BHP study area
Participants Normal birth weight neonates Low birth weight neonates Normal birth weight neonates
Number of participants 4345 1717 6048
Infant  mortality rate 47/1000 106/1000 39/1000
Dose(s) of vitamin A 50,000 IU (N = 2145) 25,000 IU (N = 854) 50,000 IU (N = 2015)
25,000 IU (N = 2011)
Placebo Yes (N = 2200) Yes (N = 863) Yes (N = 2022)
Proportion of children participating in early MV trial 2185 (50%) 130 (8%) 2826 (47%)a
Overall results of the trials
Mortality rate ratio (95% CI)
NVAS versus placebo
1.07 (0.79–1.44) 1.08 (0.79–1.47) 1.28 (0.91–1.81)
Effect  in males 0.84 (0.55–1.27) 0.74 (0.45–1.22) 1.35 (0.84–2.16)
Effect  in females 1.39 (0.90–2.14) 1.42 (0.94–2.15) 1.21 (0.73–2.01)
Results when censoring children at the date they received early measles vaccine
Mortality rate ratio (95% CI)
NVAS versus placebo
1.02 (0.76–1.38) 1.08 (0.79–1.46) 1.18 (0.84–1.68)
Effect  in males 0.81 (0.53–1.23) 0.74 (0.46–1.20) 1.22 (0.76–1.97)
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a One more than reported in VITA III; this child was excluded from VITA III becau
he usual MV  at 9 months of age was also conducted [5,6]. When
nalyzing the data from the early MV  trial it became clear that there
ere strong interactions between early MV  and NVAS. Early MV  had
o effect on overall mortality in children who had received NVAS,
hereas a strong beneﬁcial effect was seen among children who
ad not received NVAS, either because they had been randomized
o placebo or because they had not participated in the NVAS trials
5].
Though neither NVAS nor early MV  is currently recommended,
he situation may  change. Three new NVAS trials are ongoing [7]
nd NVAS may  become policy if these new trials show a beneﬁcial
ffect. The early MV  trial showed a remarkably strong beneﬁcial
ffect of early MV in children who had not received NVAS. The
rial is currently being repeated in several West African countries
hich do not use NVAS. If results are replicable early MV may  also
ecome policy. It is therefore important to assess whether there is
nteraction between NVAS and early MV.
In the present paper we analyzed the potential interaction
etween NVAS and early MV  in 5141 children who  participated in
oth an NVAS trial and the early MV  trial. We  compared the mortal-
ty of NVAS and placebo recipients: ﬁrst, in the time window from
.5 to 8 months for children randomized to early MV  or no early
V,  and second, from 9 to 17 months in children who had received
wo MV or one MV,  respectively.
. Methods
The study was a reanalysis of previously conducted randomized
rials of NVAS and early MV,  respectively. The trials were conducted
o study the effect of NVAS and MV,  respectively, and the idea
o study the potential interactions between the two interventions
nly occurred after the completion of the trials. Hence, the size of
he present study was not based on a prespeciﬁed hypothesis and
orresponding sample size calculations, but deﬁned by the num-
er of children who had participated in both a NVAS trial and the
arly MV  trial. Information on exposure (randomization to NVAS
nd early MV)  and outcome (overall mortality) was  available from
he trial databases..1. Setting
The Bandim Health Project (BHP) maintains a demographic
urveillance system in six suburban districts of the capital of1.43 (0.94–2.16) 1.14 (0.68–1.90)
 weight was  below 2.5 kg.
Guinea-Bissau and covers approximately 102,000 inhabitants.
There are three health centers in the study area, one has a maternity
ward. The national hospital where many women from the study
area give birth is a few kilometers away. BHP assistants are placed
at the health centers and the hospital to register all study area chil-
dren. All houses in the study area are visited monthly to register
new pregnancies and births. All children below 3 years of age are
followed through home visits every third month.
UNICEF classiﬁes Guinea-Bissau as having vitamin A deﬁciency
as a public health problem [8]. The country has implemented VAS
campaigns for children between 6 months and 5 years of age. Dur-
ing the study period there were vitamin A campaigns in November
2003, December 2004, December 2005, May 2006, November 2006,
July 2007, December 2007, July 2008, and January 2009.
2.2. Vitamin A trials
From 2002 to 2008, we conducted three trials of NVAS. VITA
I randomized normal birth weight neonates (≥2500 g) 1:1 to
50,000 IU vitamin A or placebo (2002–2004) [1]. VITA II random-
ized low birth weight neonates (<2500 g) 1:1 to 25,000 IU vitamin
A or placebo (2005–2008) [2]. VITA III randomized normal birth
weight neonates 1:1:1 to 50,000 IU vitamin A, 25,000 IU vitamin A
or placebo (2004–2007) [3]. The trials are presented in more detail
in Table 1.
2.3. Early MV trial
The Early MV  trial enrolled 4.5 months old children from August
2003 to April 2007 as described in detail elsewhere [5]. Children
were randomized 1:1:1 to three treatment groups: a standard dose
of Edmonston-Zagreb (EZ) MV  at 4.5 months of age and at 9 months
of age (group A); no vaccine at 4.5 months and EZ MV at 9 months
of age (group B); no vaccine at 4.5 months and Schwarz MV  at 9
months of age (group C). All children were enrolled and randomized
at 4.5 months of age. It was a condition for entering the trial that
the children had received the third dose of DTP (DTP3) at least four
weeks before enrollment; hence, children in groups B and C had
DTP3 as their most recent vaccination between 4.5 and 8 months
of age. Children in groups B and C who received MV  at 9 months of
age were randomized to an additional MV  or no additional MV  at
18 months of age. We  found no differences between groups B and
C, and hence the two  groups have been combined [5].
5470 C.S. Benn et al. / Vaccine 32 (2014) 5468–5474
Table  2
Characteristics at enrollment into the early measles vaccine trial among children randomized to vitamin A and placebo at birth and measles vaccine or no measles vaccine
at  4.5 months of age.a
Early measles vaccine (N = 1700) No early measles vaccine (N = 3441)
Vitamin A (N = 1022) Placebo (N = 678) Vitamin A (N = 1993) Placebo (N = 1448)
Male sex 51% (526) 52% (350) 51% (1021) 51% (733)
Median age (25–75% range) at enrollment (months) 4.8 (4.7, 5.1) 4.8 (4.7, 5.2) 4.8 (4.7, 5.2) 4.8 (4.6, 5.1)
Enrollment in rainy season 52% (529) 47% (321) 51% (1009) 50% (729)
Bandim suburb 45% (456) 47% (317) 44% (871) 46% (672)
Breastfed at enrollment 96% (981) 97% (655) 97% (1921) 96% (1388)
Exclusively breastfed at enrollment (among breastfed) 21% (201) 19% (125) 23% (429) 22% (300)
Hospitalized before enrollment 3% (26) 4% (27) 3% (50) 2% (28)
Pigs  in household 17% (171) 16% (104) 19% (368) 17% (250)
Median no of people/sleeping room (25–75% range) 4 (3–5) 4 (3–5) 4 (3–5) 4 (3–5)
Toilet  inside house 18% (179) 15% (102) 15% (293) 15% (217)
Functioning electricity 25 (252) 28 (187) 27 (537) 26 (370)
Mean  weight in kg (SD) 7.2 (0.96) 7.2 (0.96) 7.2 (0.99) 7.2 (1.00)
Mean  weight-for-age z-score (SD)d −0.08 (1.11) −0.02 (1.10) −0.07 (1.11) −0.09 (1.16)
Mean  length in cm (SD) 64.3 (2.6) 64.3 (2.7) 64.2 (2.8) 64.1 (2.6)
Mean  length-for-age z-score (SD)d −0.28 (1.13) −0.32 (1.18) −0.31 (1.21) −0.34 (1.19)
Mean  weight-for-length z-score (SD)d 0.22 (1.24) 0.32 (1.29) 0.26 (1.30) 0.25 (1.34)
Mean  MUAC in mm (SD) 142.2 (11.7) 142.6 (11.6) 142.6 (12.0)b 141.6 (12.2)b
Mean maternal MUAC in mm (SD) 277.7 (35.1) 274.4 (33.4) 275.6 (34.2) 274.8 (34.2)
NBW  VITA I 377 (52%)c 342 (48%)c 703 (48%)c 763 (52%)c
LBW VITA II 19 (50%) 19 (50%) 46 (50%) 46 (50%)
NBW  VITA III 626 (66%) 317 (34%) 1244 (66%) 639 (34%)
a Compared using chi-square test (categorical variables), t-test (normally distributed continuous variables), and Kruskall–Wallis test (non-normally distributed continuous
variables, only age at enrollment and people/sleeping room).
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c p = 0.05 for equal distribution of NVAS and placebo in the early MV and the no e
d Computed using the WHO  Child Growth Standards (Software available at http:/
.4. Outcome
The vitamin A trials had mortality by 12 months of age as main
utcome; the early MV  trial had mortality by 3 years of age as main
utcome. In the present reanalysis we studied the effect of NVAS
ersus placebo between 4.5 and 8 months of age, when the children
ad early MV or DTP3 as their most recent vaccine, and from 9 to 17
onths, when the children according to the protocol had two  doses
f MV or one dose of MV  as their most recent vaccine. Follow-up
as censored at age 18 months when children in the one-dose MV
roup were randomized to a booster dose of MV  or no booster and
any children received booster DTP.
.5. Ethical issues
The trials were registered at clinicaltrials.gov (VITA I:
CT00168597; VITA II and III: NCT00168610; Early MV trial:
CT00168558). All trials were approved by the Research Coor-
ination and Ethical Committee of the Ministry of Health in
uinea-Bissau and the Danish Central Ethical Committee gave its
onsultative approval.
.6. Statistical analysis
All analyses were done using Stata 12.1 (StataCorp, College
tation, TX).
Characteristics at enrollment into the early MV trial were com-
ared using chi-square test (categorical variables), t-test (normally
istributed continuous variables), and Kruskall–Wallis test (non-
ormally distributed continuous variables).
We  compared mortality rates (MR) between NVAS and placebo
ecipients within strata of early and no early MV  in Cox proportional
azards models with age as the underlying time variable. Hence,
ge was inherently adjusted for. All analyses were furthermore
djusted for NVAS trial (VITA I–III). (t-test).
V group in VITA I (chi-square test).
.who.int/nutgrowthdb/software/en/).
In the analysis between 4.5 and 8 months of age the children
entered at the date of randomization to MV or no early MV  and
were censored at the date of the 9-month-MV; in the analysis from
9 to 17 months the children entered at the date of the 9-month
MV  and were censored at age 18 months. Children who were lost
to follow-up were censored at the date when they were last seen
alive. As NVAS may  interact with subsequent VAS [9] we  conducted
an analysis in which we  censored children at the time of the ﬁrst
VAS opportunity after they reached 6 months of age.
Finally we calculated a combined estimate of the three NVAS
trials with censoring of children at the time of early MV.
The analyses were post hoc analyses in the sense that the orig-
inal trials were not designed to test the potential interaction, but
prespeciﬁed in the sense that we conceived the idea to study the
interaction, based on observations from other studies, prior to con-
ducting the analyses.
All the analyses are interaction analyses, since we evaluated
NVAS effects in strata of the NVAS trial participants, namely those
who did and those who did not receive early MV.  The interaction
analyses were stratiﬁed by sex, as both the NVAS and the early MV
trial found sex-differences. They were also stratiﬁed by the two  age
windows (4.5–8 months and 9–17 months) which were inherent
in the design of the early MV  trial. Hence, the potential interac-
tion between NVAS and early MV  was assessed overall and in 4
subgroups deﬁned by sex and age. We did not perform other inter-
action analyses than those described. With this limited number of
subgroup analyses we  did not ﬁnd it indicated to adjust for multiple
testing.
3. Results
A total of 5141 children participated both in NVAS trials and in
the early MV  trial; 2185 (42.5%) participated in VITA I, 130 (2.5%)
in VITA II, and 2826 (55.0%) in VITA III.
The random allocation seemed conserved at age 4.5 months
as the baseline characteristics at enrollment was  evenly
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Table  3
Mortality rate ratios in different age groups according to randomization to neonatal vitamin A supplementation (NVAS) or placebo and early or no early measles vaccine
(MV).  Note: all children received MV at 9 months of age.a
NVAS (N= 3015)
Mortality rate 
(N/pyrs)
Pla cebo (N=2126)
Mortality rate 
(N/pyrs)
Mortality ra te ra tio 
(95% CI)
2
P for same effect  of 
NVAS in Early MV 
versus No early MV 
groups 
0.03
3
4.5-8 months
Early MV (N=1700) 30 (11/370) 0 (0/246) P=0.01
2
- Male (N=875)  37 (7/190) 0 (0/128) 0.052
- Female (N=82 5) 22 (4/180) 0 (0/118) 0.122
No early MV (N=3441) 26 (19/724) 25 (13/526) 1.26 (0.61, 2.58)
- Male (N=1754) 16 (6/374) 19 (5/266) 1.01 (0.31, 3.34)
- Female (N=1687) 37 (13/350) 31 (8/260) 1.43 (0.59, 3.49)
0.09
9-17  months
Early MV 18 (12/666) 7 (3/443) 2.81 (0.79, 9.99)
- Male  27 (9/338) 4 (1/231) 6.77 (0.86, 53.58)
- Female  9 (3/328) 9 (2/212) 0.99 (0.17, 5.96)
No early MV 18 (22/1224)    23 (21/898) 0.82 (0.45, 1.51)
- Male  16 (10/624)  20 (9/450) 0.91 (0.36, 2.26)
- Female 20 (12/599) 27 (12/448) 0.77 (0.34, 1.72)
0.008
4.5-17  months
Early MV 22 (23/1036) 4 (3/689) 5.39 (1.62, 17.99)
- Male  30 (16/528) 3 (1/358) 11.31 (1.50, 85.47)
- Female  14 (7/508) 6 (2/331) 2.46 (0.51, 11.85)
No early MV 21 (41/1947) 24 (34/1423) 0.95 (0.60, 1.50)
- Male  16 (16/998) 20 (14/716) 0.86 (0.42, 1.78)
Bold text marks signiﬁcant differences at the 5% level.
pyrs = person-years of risk.
a Mortality rate ratio estimates derived from Cox proportional hazards models adjusted for Trials I–III.
b Note that it was  not possible to calculate mortality rate ratio for the early MV group from 4.5 to 8 months; instead we  calculated a p-value for equal mortality rates using
l
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p-value from exact Poisson regression using command expoisson in Stata.
istributed between NVAS and placebo groups except that
lightly more NVAS recipients in VITA I were allocated to early MV,
nd NVAS recipients compared with placebo recipients in the no
arly MV  group had very slightly higher mid-upper-arm circum-
erence (MUAC) (Table 2). Ninety-six percent of the children were
reastfed at enrollment; 22% of these were exclusively breastfed.
y 9 months of age, 92% were still breastfed, the proportions at
oth time points were similar in males and females (data not
hown).
Between enrollment into the early MV  trial and 9 months of
ge, at the time of the usual MV,  43 deaths occurred in 1865 pyrscorresponding to a mortality rate (MR) of 23/1000 pyrs. However,
the MR  varied between the different groups (Fig. 1). In the early
MV group having received NVAS was associated with signiﬁcantly
higher mortality compared with placebo (MR = 30 versus MR = 0,
p = 0.01, Table 3). The effect was  signiﬁcant in males (p = 0.05) but
not in females (p = 0.12). When comparing the effect of NVAS in
the early MV  group with the effect of NVAS in the no early MV
group, the effect of NVAS was  more marked in the early MV group
than in the no early MV  group (MR  = 26 versus MR = 25), resulting
in a signiﬁcant interaction between NVAS and early MV  (p = 0.03,
Table 3).
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Femalesig. 1. Cumulative mortality according to randomization to neonatal vitamin A
upplementation (NVAS) and early measles vaccine (MV), from 4 to 8 months.
As expected the MR  was lower between 9 and 17 months of age
58 deaths/3231 pyrs, MR  = 18/1000). There was no longer any sig-
iﬁcant negative effect of receiving NVAS compared with placebo
n the early MV group (Table 3, Fig. 2)
Between 4.5 and 17 months of age, due to the strong negative
ffect observed up to 9 months of age, NVAS compared with placeboFig. 2. Cumulative mortality according to randomization to neonatal vitamin A
supplementation (NVAS) and early measles vaccine (MV), from 9 to 17 months.
was associated with signiﬁcantly increased mortality in early MV
recipients, overall (5.39 (1.62, 17.99)) and in males (11.31 (1.50,
85.47)), again resulting in a signiﬁcant interaction between NVAS
and early MV  (p = 0.008, Table 3).
When we censored follow-up at the time of the ﬁrst vitamin A
opportunity occurring after the children had reached 6 months of
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ge, the results remained largely unchanged (from 4.5 to 17 months
f age the estimate for NVAS versus placebo was  4.28 (1.25–14.62);
.16 (1.05–63.42) in males).
.1. Effect of neonatal VAS in all previous trials when censoring
or early MV
We  conducted a reanalysis of VITA I–III to assess the effect of
eonatal VAS on infant mortality if we censored children when they
eceived early MV.  The estimates for the three trials are shown in
able 1. The combined estimate for the three trials was 1.08 (0.90,
.30); 0.89 (0.69, 1.16) in males and 1.31 (1.01, 1.70) in females (p
or same effect in males and females = 0.04).
. Discussion
In this analysis we combined information on children who  had
articipated ﬁrst in an NVAS trial, and subsequently in an early MV
rial, and found signiﬁcant interactions between the two immune-
odulatory interventions. Having received NVAS as compared with
lacebo was associated with a strong negative effect on overall
ortality after receiving early MV.  The negative effect was pro-
ounced from 4.5 to 8 months of age. It was signiﬁcant in its own
ight among males.
None of the three NVAS trials from Guinea-Bissau found a
eneﬁcial effect [1–3]. Some children from all three trials also par-
icipated in the early MV  trial, and a negative interaction between
VAS and early MV  could have led to an underestimation of the
eneﬁts of NVAS for children, who follow the currently recom-
ended vaccination schedule. However, a reanalysis of the three
rials with censoring at the time of early MV  still showed no ben-
ﬁcial effect of NVAS and a signiﬁcant negative effect in females.
ence, early MV does not explain the lack of beneﬁcial effect of
VAS in Guinea-Bissau.
.1. Strengths and weaknesses
Though this analysis should not be interpreted as a 2-by-2 fac-
orial trial it still has some of the strengths of a trial, as the children
ere randomized to both treatments. However, it is a relatively
mall study, it was not sized to study interactions, and it may  be
ubject to random ﬂuctuations in mortality among subgroups.
.2. Interpretation
More than 10 years ago, our group proposed the hypothesis
hat VAS ampliﬁes the non-speciﬁc effects of vaccines [10]. This
ypothesis was based on two main observations: ﬁrst, the routine
hildhood vaccinations have non-speciﬁc effects, the live BCG and
V reduce mortality more than can be explained by prevention of
he target diseases [11,12], whereas the inactivated DTP vaccine is
ssociated with increased mortality in areas with herd immunity
o pertussis [13,14]; second, the mortality beneﬁt pattern after VAS
esembles that of vaccines, with a beneﬁcial effect in the time win-
ows dominated by BCG (at birth) and MV (after 6 months of age)
ut no beneﬁcial effect between 1 and 5 months of age, in the time
indow of DTP [10]. The hypothesis implied that VAS would prob-
bly be beneﬁcial when provided with the live BCG and MV,  but
armful when provided with DTP vaccine. We  have subsequently
ested the hypothesis in observational studies [15,16], randomized
rials [1–3,17] and by reanalyzing old trials [18] and we have been
ble to show repeatedly that VAS and vaccines interact.We  have also learned in the process. Initially, we did not empha-
ize sex as an important covariate. However, in most [1,2,4,17,18],
hough not all studies [3,15,16], we have found that VAS provided
lose to DTP had a negative effect for females, but not for males. (2014) 5468–5474 5473
Furthermore, we  had not envisaged that VAS could interact with
vaccines given months after. We  ﬁrst became aware of this pos-
sibility when analyzing the ﬁrst NVAS trial, observing an increase
in mortality in female NVAS recipients, which occurred when the
children started receiving DTP several months after NVAS [4]. The
present analysis suggests that NVAS may  interact with vaccines
given as much as 4–5 months later. If true, this is surprising, not only
because it occurred so many months after NVAS, but also because
the interaction between NVAS and early MV was negative. If any-
thing we  would have expected the opposite. The explanation may
be the three intermediate DTP vaccinations. In the early MV trial, all
children were visited at the ages of DTP1, DTP2, and DTP3 and their
mothers were encouraged to bring them for vaccination. Hence, all
participants had received three DTP vaccines with short intervals,
and they were enrolled in the early MV  trial 4 weeks later. The cock-
tail of ﬁrst NVAS, then three DTP and then early MV may  have been
too much. In a trial of BCG revaccination we found a negative effect
of receiving BCG at 19 months of age followed by DTP and then VAS
in a campaign [19].
4.3. Biological mechanisms
We have discovered interactions between NVAS and the fol-
lowing vaccines: DTP (negative for females) [2,4], and early MV
(negative for males). Furthermore, we have found that NVAS primes
a beneﬁcial response to a subsequent dose of VAS provided after 12
months of age, particularly in females [9,16]. Hence, NVAS seems
to have profound effects on the immune system’s response to sub-
sequent stimulations with both vaccines and micronutrients – and
these effects may  differ in males and females.
A single high dose of vitamin A will quickly be distributed into
the tissues and only released under homeostatic control. It may help
prevent vitamin A deﬁciency, but it seems unlikely that this would
have so profound long-term effects on the response to vaccines.
A recent review has addressed vitamin A’s potential epigenetic
effects and emphasized vitamin A’s powerful effects on stem cell
differentiation [20]. From our perspective the most plausible expla-
nations for the observed long-term effects of NVAS is that NVAS has
epigenetic effects, resulting in fundamental priming effects on the
neonatal immune system which determine the response to subse-
quent challenges. The result may  be a reduction in mortality after
the child receives MV at 9 months of age or after a subsequent high
dose of vitamin A – but the present study indicated that it primes
for a detrimental response to an early MV  given shortly after three
doses of DTP.
4.4. Implications
Though the existing four NVAS trials in Africa have all shown
negative trends [1–3,21,22], three new NVAS trials are ongoing [7].
NVAS may become policy if these new trials show a beneﬁcial effect.
This could potentially happen if the trials are carried out in areas
with high neonatal mortality but low subsequent mortality, or in
areas with combined BCG and DTP vaccination – in such areas a
negative interaction between NVAS and DTP in females would not
be seen. If introduced, it will be very important to ensure that NVAS
does not interact negatively with DTP in females, and to be alert
about potential interactions with other health interventions. MV is
currently being recommended from age 6 months of age in areas
with a high incidence of both HIV infection and measles [23]. Hence,
if NVAS is being introduced it is possible that it may  have negative
long-term effects on overall mortality in such settings. The early
MV trial is being repeated in two  African countries of which none
uses NVAS, and if the results are replicable early MV  may become
a common policy. If there are indeed negative interaction between
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VAS and early MV  it will be important that the two policies are
ot both implemented.
onclusion
The present study adds to the evidence that VAS interacts with
accines. The interactions may  sometimes be beneﬁcial but some-
imes negative, increasing mortality. The interactions between
ealth interventions are not considered when global policies are
esigned and implemented. However, with the trend to co-package
nterventions, it should become increasingly important to consider
nteractions to optimize the beneﬁcial effect of child intervention
rograms.
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